BIO logo

Bio-Rad Laboratories (BIO)

Profile

Full Name

Bio-Rad Laboratories, Inc.

Ticker Symbol

BIO

Exchange

NYSE

Country

United States

IPO

February 27, 1980

Indexes

Not included

Employees

7700

Key Details

Price

$234.75

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$2.57B(-3.92% YoY)

Annual EPS

-$65.36(-199.54% YoY)

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Feb 12, 25 Wells Fargo
Equal-Weight
Jan 14, 25 RBC Capital
Outperform
Dec 9, 24 RBC Capital
Outperform
Oct 31, 24 RBC Capital
Outperform
Oct 31, 24 Citigroup
Buy
Oct 1, 24 Citigroup
Buy
Aug 27, 24 Wells Fargo
Equal-Weight
Aug 16, 24 RBC Capital
Outperform
Aug 2, 24 RBC Capital
Outperform
Aug 2, 24 Citigroup
Neutral

Institutional Ownership

  • What is the ticker symbol for Bio-Rad Laboratories?
  • Does Bio-Rad Laboratories pay dividends?
  • What sector is Bio-Rad Laboratories in?
  • What industry is Bio-Rad Laboratories in?
  • What country is Bio-Rad Laboratories based in?
  • When did Bio-Rad Laboratories go public?
  • Is Bio-Rad Laboratories in the S&P 500?
  • Is Bio-Rad Laboratories in the NASDAQ 100?
  • Is Bio-Rad Laboratories in the Dow Jones?
  • When was Bio-Rad Laboratories's last earnings report?
  • When does Bio-Rad Laboratories report earnings?
  • Should I buy Bio-Rad Laboratories stock now?

What is the ticker symbol for Bio-Rad Laboratories?

The ticker symbol for Bio-Rad Laboratories is NYSE:BIO

Does Bio-Rad Laboratories pay dividends?

No, Bio-Rad Laboratories does not pay dividends

What sector is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Healthcare sector

What industry is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Medical Devices industry

What country is Bio-Rad Laboratories based in?

Bio-Rad Laboratories is headquartered in United States

When did Bio-Rad Laboratories go public?

Bio-Rad Laboratories's initial public offering (IPO) was on February 27, 1980

Is Bio-Rad Laboratories in the S&P 500?

No, Bio-Rad Laboratories is not included in the S&P 500 index

Is Bio-Rad Laboratories in the NASDAQ 100?

No, Bio-Rad Laboratories is not included in the NASDAQ 100 index

Is Bio-Rad Laboratories in the Dow Jones?

No, Bio-Rad Laboratories is not included in the Dow Jones index

When was Bio-Rad Laboratories's last earnings report?

Bio-Rad Laboratories's most recent earnings report was on Feb 13, 2025

When does Bio-Rad Laboratories report earnings?

The next expected earnings date for Bio-Rad Laboratories is May 7, 2025

Should I buy Bio-Rad Laboratories stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page